BIO Notebook: GSK’s Walmsley On M&A, Merck On How Falling Valuations Are Affecting Deals
Executive Summary
On the first day of the BIO International Convention, our reporters hear from industry leaders about tough financing, when to go public, and why ‘there shouldn't be 700 listed biotechs in the US.’
You may also be interested in...
Deal Watch: Gurnet Point, Novo Holdings Buy Out Paratek
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co takes IRA legal action; notes from BIO Day 1; stories from ASCO around ImmunoGen’s ovarian cancer candidate and Servier’s progress in glioma; and the future of AI in pharma.
Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout
Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.